117 related articles for article (PubMed ID: 7627720)
1. Abnormal liver function in patients undergoing autologous bone marrow transplantation for hematological malignancies.
Wasserheit C; Acaba L; Gulati S
Cancer Invest; 1995; 13(4):347-54. PubMed ID: 7627720
[TBL] [Abstract][Full Text] [Related]
2. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
Gulati S; Yahalom J; Acaba L; Reich L; Motzer R; Crown J; Toia M; Igarashi T; Lemoli R; Hanninen E
J Clin Oncol; 1992 Jun; 10(6):936-41. PubMed ID: 1588372
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting the outcome of autologous bone marrow transplantation.
Gulati SC; Yahalom J; Whitmarsh K; Clarkson BD; Gee T
Ann Oncol; 1991 Jan; 2 Suppl 1():51-5. PubMed ID: 2043499
[TBL] [Abstract][Full Text] [Related]
5. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
Brodsky R; Topolsky D; Crilley P; Bulova S; Brodsky I
Am J Clin Oncol; 1990 Jun; 13(3):221-5. PubMed ID: 2346127
[TBL] [Abstract][Full Text] [Related]
6. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
7. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Stone RM; Neuberg D; Soiffer R; Takvorian T; Whelan M; Rabinowe SN; Aster JC; Leavitt P; Mauch P; Freedman AS
J Clin Oncol; 1994 Dec; 12(12):2535-42. PubMed ID: 7989927
[TBL] [Abstract][Full Text] [Related]
9. High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity.
Rosenthal MA; Grigg AP; Sheridan WP
Leuk Lymphoma; 1994 Jul; 14(3-4):279-83. PubMed ID: 7524888
[TBL] [Abstract][Full Text] [Related]
10. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
McDonald GB; Hinds MS; Fisher LD; Schoch HG; Wolford JL; Banaji M; Hardin BJ; Shulman HM; Clift RA
Ann Intern Med; 1993 Feb; 118(4):255-67. PubMed ID: 8420443
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation.
Jules-Elysee K; Stover DE; Yahalom J; White DA; Gulati SC
Am Rev Respir Dis; 1992 Aug; 146(2):485-91. PubMed ID: 1489145
[TBL] [Abstract][Full Text] [Related]
12. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.
Ayash LJ; Hunt M; Antman K; Nadler L; Wheeler C; Takvorian T; Elias A; Antin JH; Greenough T; Eder JP
J Clin Oncol; 1990 Oct; 8(10):1699-706. PubMed ID: 2213105
[TBL] [Abstract][Full Text] [Related]
13. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
[TBL] [Abstract][Full Text] [Related]
14. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
17. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
Yahalom J; Gulati SC; Toia M; Maslak P; McCarron EG; O'Brien JP; Portlock CS; Straus DJ; Phillips J; Fuks Z
J Clin Oncol; 1993 Jun; 11(6):1062-70. PubMed ID: 8501492
[TBL] [Abstract][Full Text] [Related]
18. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
19. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
20. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
